ArticleBundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz2023
[PraeKids: diagnosis prevalence of life-threatening and life-limiting diseases in children and adolescents in Germany].
Article in Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 3 citations in OpenAlex.
- Prevalence and Mortality of Life-Threatening and Life-Shortening Diseases in Children and Adolescents in Germany.Clinical pediatrics · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionIn Germany, a prevalence of approximately 50,000 children and adolescents living with life-threatening and life-limiting diseases is currently assumed. This number, which is communicated in the supply landscape, is based on a simple transfer of empirical data from England.
methodsIn cooperation with the German National Association of Health Insurance Funds (GKV-SV) and the Institute for Applied Health Research Berlin GmbH (InGef), the billing data of the specific treatment diagnoses documented by statutory health insurance funds for the years 2014-2019 were analyzed and - for the first time - prevalence data of affected 0‑ to 19-year-olds were collected. In addition, the data from InGef was used to calculate the prevalence by diagnosis grouping, the Together for Short Lives (TfSL) groups 1-4, and based on the (updated) coding lists from the English prevalence studies.
resultsThe data analysis determined a prevalence range of 319,948 (InGef - adapted Fraser list) to 402,058 (GKV-SV), with consideration of the TfSL groups. The TfSL‑1 group represents the largest group with 190,865 patients. DISCUSSION AND
conclusionThis study is the first to provide the prevalence of 0‑ to 19-year-olds living with life-threatening or life-limiting diseases in Germany. Since the case definitions and the included care settings (outpatient/inpatient) differ in the research design, the prevalence values collected from the GKV-SV and InGef are also different. Due to the very heterogeneous course of the diseases, chances of survival, and mortality rates, no direct conclusions can be drawn for palliative and hospice care structures.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.